Dr Reddy’s Laboratories (DRL) has received approval from India’s Central Drugs Standard Control Organisation (CDSCO) for Zytorvi (toripalimab), in combination with cisplatin and paclitaxel, as a first-line treatment for adults with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (ESCC). The approval provides an additional immunotherapy-based treatment option for eligible patients with advanced ESCC, […]